February 8, 2022
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy
Phase 1/2 clinical study in patients with advanced solid tumor expected to start in 2Q2022 SEONGNAM-SI, South Korea–(BUSINESS WIRE)–Qurient Co.…